ASCO News: Kidney Cancer Drug Delays Ovarian Cancer Relapse
ASCO News: Kidney Cancer Drug Delays Ovarian Cancer Relapse
Research presented at the American Society of Clinical Oncology annual meeting this week suggests that adding the drug pazopanib (trade name Votrient) to standard treatment extends progression-free survival in ovarian cancer patients by 5.6 months. Pazopanib is an oral anti-angiogenesis drug already approved to treat kidney cancer. The phase III study of over 900 women … Continued